keyword
MENU ▼
Read by QxMD icon Read
search

Lenvatinib

keyword
https://www.readbyqxmd.com/read/29331886/anti-cancer-effects-of-hnha-and-lenvatinib-by-the-suppression-of-emt-mediated-drug-resistance-in-cancer-stem-cells
#1
Yong Sang Lee, Seok-Mo Kim, Bup-Woo Kim, Ho Jin Chang, Soo Young Kim, Cheong Soo Park, Ki Cheong Park, Hang-Seok Chang
Anaplastic thyroid cancer (ATC) constitutes less than 2% of total thyroid cancers but accounts for 20-40% of thyroid cancer-related deaths. Cancer stem cell drug resistance represents a primary factor hindering treatment. This study aimed to develop targeted agents against thyroid malignancy, focusing on individual and synergistic effects of HNHA (histone deacetylase), lenvatinib (FGFR), and sorafenib (tyrosine kinase) inhibitors. Patients with biochemically and histologically proven papillary thyroid cancer (PTC) and ATC were included...
January 11, 2018: Neoplasia: An International Journal for Oncology Research
https://www.readbyqxmd.com/read/29284153/role-of-ret-protein-tyrosine-kinase-inhibitors-in-the-treatment-ret-driven-thyroid-and-lung-cancers
#2
REVIEW
Robert Roskoski, Abdollah Sadeghi-Nejad
RET is a transmembrane receptor protein-tyrosine kinase that is required for the development of the nervous system and several other tissues. The mechanism of activation of RET by its glial-cell derived neurotrophic factor (GDNF) ligands differs from that of all other receptor protein-tyrosine kinases owing to the requirement for additional GDNF family receptor-α (GFRα) co-receptors (GFRα1/2/3/4). RET point mutations have been reported in multiple endocrine neoplasia (MEN2A, MEN2B) and medullary thyroid carcinoma...
December 25, 2017: Pharmacological Research: the Official Journal of the Italian Pharmacological Society
https://www.readbyqxmd.com/read/29284110/efficacy-of-lenvatinib-a-multitargeted-tyrosine-kinase-inhibitor-on-laser-induced-cnv-mouse-model-of-neovascular-amd
#3
Xian Wei, Ting Zhang, Yuqin Yao, Shaoxue Zeng, Min Li, Haotian Xiang, Chengjian Zhao, Guiqun Cao, Minhui Li, Ran Wan, Ping Yang, Jinliang Yang
Neovascular age-related macular degeneration (AMD) is a leading cause of vision loss worldwide. Although intravitreal injection of anti-VEGF antibodies and VEGF Trap have significant clinical benefits, the complications of intravitreal injection, drug resistance and patient compliance still need to be concerned. In this study, the effects of an orally administered multi-targeted tyrosine kinase inhibitor (Lenvatinib, E7080) were evaluated in vitro and in vivo on neovascular AMD mouse model. The results showed that E7080 effectively inhibited the proliferation, migration and tubule formation of human choroidal microvascular endothelial cells (HCMECs), and suppressed the angiogenesis of zebrafish subintestinal vessels without causing malformation...
December 25, 2017: Experimental Eye Research
https://www.readbyqxmd.com/read/29275532/tyrosine-kinase-inhibitors-in-iodine-refractory-differentiated-thyroid-cancer-experience-in-clinical-practice
#4
M Molina-Vega, J García-Alemán, A Sebastián-Ochoa, I Mancha-Doblas, J M Trigo-Pérez, F Tinahones-Madueño
PURPOSE: The aim of this study is to describe our clinical experience with tyrosine kinase inhibitors (TKIs) and to evaluate their efficacy and tolerability in patients with iodine-refractory differentiated thyroid cancer (DTC). METHODS: There were 17 patients (47.1% women, mean age: 65.7) with DTC iodine-refractory (9 papillary, 2 follicular and 3 Hürthle cell), treated with TKIs: 16 with sorafenib and 1 with lenvatinib as first-line treatment; 7 required second-line treatment (4 lenvatinib and 3 axitinib)...
December 23, 2017: Endocrine
https://www.readbyqxmd.com/read/29243843/signaling-cascades-in-thyroid-cancer-increasing-the-armory-of-archers-to-hit-bullseye
#5
Faiza Abdul Rashid, Qaisar Mansoor, Hafsa Aziz, Sobia Tabassum, Waleed O Arfat, George E Naoum, Muhammad Ismail, Ammad Ahmad Farooqi
Thyroid cancer is a multifaceted and therapeutically challenging disease and rapidly accumulating experimentally verified findings have considerably improve our understanding of the molecular mechanisms which underlie its development. Substantial fraction of information has been added into existing landscape of molecular oncology and we have started to develop a sharper understanding of the underlying mechanisms of thyroid cancer. Wealth of information demystified different intracellular signaling cascades which are frequently deregulated in thyroid cancer...
December 15, 2017: Journal of Cellular Biochemistry
https://www.readbyqxmd.com/read/29239194/-immunotherapy-of-renal-cell-carcinoma
#6
A Poprach, R Lakomý, T Büchler
Treatment of renal cell carcinoma is still palliative. Targeted therapy increases response rates and prolongs overall survival and progression-free survival compared with cytokines and chemotherapy. Checkpoint inhibitors constitute the up-date of therapeutic approaches, and anti-PD-1 antibody, one checkpoint inhibitor, is now well established as a second and/or third palliative treatment for patients with renal cell carcinoma. In this study, we present the latest data from current studies on cytokines, cancer vaccines, ipilimumab, and nivolumab...
2017: Klinická Onkologie: Casopis Ceské a Slovenské Onkologické Spolecnosti
https://www.readbyqxmd.com/read/29234629/lenvatinib-in-advanced-hepatocellular-carcinoma
#7
EDITORIAL
Masatoshi Kudo
No abstract text is available yet for this article.
November 2017: Liver Cancer
https://www.readbyqxmd.com/read/29225265/posterior-reversible-encephalopathy-syndrome-after-lenvatinib-therapy-in-a-patient-with-anaplastic-thyroid-carcinoma
#8
Yoko Osawa, Rikako Gozawa, Keisuke Koyama, Takeo Nakayama, Tadashi Sagoh, Hiroshi Sunaga
Posterior reversible encephalopathy syndrome (PRES) is a rare reversible neurological syndrome that causes subcortical vasogenic brain edema and which is associated with the use of target-specific agents. Lenvatinib is a target-specific agent that was recently approved for inoperable thyroid cancer. We herein describe the case of a 66-year-old woman with anaplastic thyroid cancer (ATC) who was treated with lenvatinib and who subsequently developed PRES. The clinical and radiological findings improved after suspending therapy for 1 week, and there was no recurrence with intermittent lower-dose lenvatinib treatment...
December 8, 2017: Internal Medicine
https://www.readbyqxmd.com/read/29209273/updates-on-the-management-of-advanced-metastatic-and-radioiodine-refractory-differentiated-thyroid-cancer
#9
REVIEW
Dario Tumino, Francesco Frasca, Kate Newbold
Differentiated thyroid cancer (DTC) accounts for 95% of all thyroid cancers and is generally an indolent tumor, treated effectively with surgery, radioactive iodine, and thyroid-stimulating hormone suppressive therapy. However, 5-10% of patients have advanced disease, with aerodigestive tract invasion, distant metastases, or radioiodine refractory disease, with poor prognosis. This review focuses on the approaches for treating advanced DTC, including management of gross extra-thyroidal extension, recurrent loco-regional or distant metastatic disease, the role of external beam radiation therapy and systemic treatment...
2017: Frontiers in Endocrinology
https://www.readbyqxmd.com/read/29201215/contrast-enhanced-computerized-tomography-combined-with-a-targeted-nanoparticle-contrast-agent-for-screening-for-early-phase-non-small-cell-lung-cancer
#10
Ninglu Yuan, Xiaohe Zhang, Yonghui Cao, Xiaojie Jiang, Si Zhao, Yingying Feng, Yimeng Fan, Zhitao Lu, Hongmei Gao
Non-small cell lung cancer (NSCLC) is a major cause of morbidity and mortality, and patients with NSCLC are frequently diagnosed at an advanced stage. This is primarily due to a lack of advanced and sensitive protocols for the detection of early stage NSCLC. Therefore, methods for the accurate diagnosis of early stage NSCLC are urgently required to improve survival rates. The present study investigated the use of contrast-enhanced computerized tomography (CECT) combined with a targeted nanoparticle contrast agent (TNCA) to diagnose early-stage NSCLC in a mice xenograft model...
November 2017: Experimental and Therapeutic Medicine
https://www.readbyqxmd.com/read/29198329/examining-the-bleeding-incidences-associated-with-targeted-therapies-used-in-metastatic-renal-cell-carcinoma
#11
REVIEW
MacKenzie Crist, Elizabeth Hansen, Lipika Chablani, Elizabeth Guancial
A systematic review was conducted to illustrate the bleeding risks associated with targeted therapies used in the treatment of metastatic renal cell carcinoma (mRCC). Eligible studies included phase II, III, or IV clinical trials using pazopanib, sunitinib, cabozantinib, lenvatinib, everolimus, temsirolimus, bevacizumab, axitinib, and/or sorafenib in the setting of mRCC. Types of bleeding event(s), bleeding event frequency, and incidence of thrombocytopenia were collected from the relevant articles. ClinicalTrials...
December 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/29183164/network-meta-analysis-of-second-line-treatment-in-metastatic-renal-cell-carcinoma-efficacy-and-safety
#12
Elie El Rassy, Fouad Aoun, Ghassan Sleilaty, Joseph Kattan, Bonaventure Banyurwabuke, Marc Zanaty, Ziad Bakouny, Simone Albisinni, Alexandre Peltier, Thierry Roumeguere
This paper aims to compare the approved second-line treatment options in metastatic renal cell carcinoma. A network meta-analysis (NMA) using the frequentist approach and generalized pairwise modeling was computed for the approved drugs in this setting. The results of this NMA showed that the combination of lenvatinib and everolimus yielded the lowest hazard ratio (HR) for progression-free survival (HR: 0.4; 95% CI: 0.21-0.75) and overall survival (HR: 0.55; 95% CI: 0.30-1.00). The great efficacy of this combination is limited by the prevalence of grade 3-4 adverse events (70...
December 2017: Future Oncology
https://www.readbyqxmd.com/read/29167691/long-term-efficacy-and-safety-of-fourth-line-multikinase-inhibitor-treatment-with-lenvatinib-in-a-young-papillary-thyroid-carcinoma-patient
#13
S Morelli, E Puxeddu
Lenvatinib, a multikinase inhibitor, is approved for the treatment of patients with radioiodine-refractory metastatic thyroid cancer on the basis of a Phase III, prospective, double-blind, randomized, placebo-controlled trial that showed longer progression-free survival in the drug-treated arm. Here, we report the case of a young papillary thyroid cancer patient, pretreated with three other kinase inhibitors, who achieved a long-term clinical benefit from lenvatinib in the fourth-line setting.
2017: Drugs in Context
https://www.readbyqxmd.com/read/29161986/real-world-experience-with-targeted-therapy-for-the-treatment-of-anaplastic-thyroid-carcinoma
#14
Priyanka Iyer, Ramona Dadu, Renata Ferrarotto, Naifa Busaidy, Mouhammed Amir Habra, Mark Zafereo, Neil D Gross, Kenneth Hess, Maria Gule-Monroe, Michelle D Williams, Maria Cabanillas
BACKGROUND: Patients with anaplastic thyroid cancer (ATC) have a dismal prognosis despite systemic cytotoxic chemotherapy. Our objective was to study the efficacy and safety of targeted therapy in ATC patients when used outside of a clinical trial. METHODS: This is a retrospective review from April 2015 to May 2016 at a single academic institution where we studied 16 ATC patients receiving targeted therapy outside of a clinical trial. Ten patients (8 BRAF wild-type and 2 BRAF V600E mutant) were started on lenvatinib and 6 with BRAF V600E mutated tumors received the combination of dabrafenib plus trametinib...
November 22, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29118352/thyroid-cancer-lenvatinib-beyond-trials
#15
Claire Greenhill
No abstract text is available yet for this article.
November 9, 2017: Nature Reviews. Endocrinology
https://www.readbyqxmd.com/read/29095527/clinical-guidance-for-radioiodine-refractory-differentiated-thyroid-cancer
#16
Matti L Gild, Duncan J Topliss, Diana Learoyd, Francis Parnis, Jeanne Tie, Brett Hughes, John P Walsh, Donald Sa McLeod, Roderick J Clifton-Bligh, Bruce G Robinson
Prognosis from differentiated thyroid cancer is worse when the disease becomes refractory to radioiodine. Until recently, treatment options have been limited to local therapies such as surgery and radiotherapy, but the recent availability of systemic therapies now provides some potential for disease control. Multi-targeted kinase inhibitors (TKIs) including lenvatinib and sorafenib have been shown to improve progression free survival in Phase III clinical trials, but are also associated with a spectrum of adverse effects...
November 2, 2017: Clinical Endocrinology
https://www.readbyqxmd.com/read/29057760/anaplastic-thyroid-carcinoma-treated-with-lenvatinib
#17
Jun-Ichi Ohkubo, Azusa Takahashi, Shoji Ikezaki, Fumiko Takenaga, Yufu Ohkubo, Hideaki Suzuki
OBJECTIVE: We report a case of anaplastic thyroid carcinoma (ATC) with local recurrence and distant metastasis that responded very well to treatment with lenvatinib, a new molecular-targeted anticancer drug. CASE REPORT: A 91-year-old Japanese woman presented with a 5-month history of a painless mass in her left anterior neck. She had a past history of total thyroidectomy and neck dissection for papillary carcinoma of the thyroid. Here she underwent neck dissection, and the histopathological diagnosis was lymph node metastasis of papillary carcinoma with anaplastic transformation...
October 20, 2017: Kurume Medical Journal
https://www.readbyqxmd.com/read/29055877/surgical-treatment-of-locally-advanced-papillary-thyroid-carcinoma-after-response-to-lenvatinib-a-case-report
#18
Mitsuhiro Tsuboi, Hiromitsu Takizawa, Mariko Aoyama, Akira Tangoku
INTRODUCTION: Differentiated thyroid carcinomas (DTC) have good prognoses after complete resection. Nevertheless, when DTC is associated with an aerodigestive invasion, curative surgery is difficult to perform. However, there is no established neoadjuvant therapy for advanced DTC. PRESENTATION OF CASE: A 73-year-old man with thyroid papillary carcinoma was referred to our hospital. A computed tomography examination revealed a tumor in the upper right lobe of the thyroid, and multiple bilateral enlarged lymph nodes in the neck, involving the surrounding structures...
October 14, 2017: International Journal of Surgery Case Reports
https://www.readbyqxmd.com/read/29048237/lenvatinib-for-the-treatment-of-radioiodine-refractory-thyroid-cancer-in-real-life-practice
#19
Amandine Berdelou, Isabelle Borget, Yann Godbert, Thierry Nguyen, Marie-Eve Garcia, Cécile N Chougnet, Aurélie Ferru, Camille Buffet, Olivier Chabre, Olivier Huillard, Sophie Leboulleux, Martin Schlumberger
BACKGROUND: In the Study of (E7080) Lenvatinib in Differentiated Cancer of the Thyroid (SELECT) phase 3 trial on advanced radioactive iodine-refractory differentiated thyroid cancer (rDTC), lenvatinib improved median progression-free survival over placebo by almost 15 months and induces an objective response rate of 64.8%, but adverse events occurred in almost all patients. The present study evaluates the efficacy and toxicity of lenvatinib treatment in real-life practice. METHODS: Clinical charts of 88 consecutive patients treated with lenvatinib from July 2015 to June 2016 in 27 French centers were retrospectively reviewed...
November 27, 2017: Thyroid: Official Journal of the American Thyroid Association
https://www.readbyqxmd.com/read/29034773/substrate-dependent-effects-of-molecular-targeted-anticancer-agents-on-activity-of-organic-anion-transporting-polypeptide-1b1
#20
Hiroyoshi Koide, Masayuki Tsujimoto, Ai Takeuchi, Miyu Tanaka, Yoko Ikegami, Mayu Tagami, Syoko Abe, Miki Hashimoto, Tetsuya Minegaki, Kohshi Nishiguchi
1. Organic anion-transporting polypeptide 1B1 (OATP1B1) plays an important role in the hepatic uptake of a broad range of substrate drugs. In vitro experiments show that molecular-targeted agents do not always have similar effects on OATP1B1 activity. 2. The purpose of this study was to clarify whether the effects of molecular-targeted agents on OATP1B1 are substrate-dependent. We used OATP1B1-transfected cells to compare the effects of molecular-targeted agents on OATP1B1-mediated uptake of fluorescein (FL), 2',7'-dichlorofluorescein (DCF), atorvastatin, SN-38, and valsartan...
October 16, 2017: Xenobiotica; the Fate of Foreign Compounds in Biological Systems
keyword
keyword
72038
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"